TOR ( target of rapamycin) signaling Apr 4, 2005.

Slides:



Advertisements
Similar presentations
Inhibition of the mTOR and MAPK pathways in the treatment of osteosarcoma Kathleen M. Diehl, M.D. FACS Assistant Professor University of Michigan.
Advertisements

Insulin Signaling – Insulin Resistance Elmus G. Beale, Professor Texas Tech University Health Sciences Center Paul L. Foster School of Medicine PhD, Baylor.
TSC2 and Tuberous Sclerosis Complex Disease Laura Koontz Biology 169.
Chemical Genomics – Biol503 Lecture 2 Chemical Genomics and cancer/cardiovascular diseases.
HCVM Member of  -herpesvirus family >200 ORFs Genes are expressed in a regulated cascade Some fulfill regulatory functions pUL38 expression during early.
Phosphatase and Tensin Homolog Deleted on Chromosome 10
The Cell Cycle.
Targeting the IGF Pathway in Pediatric Sarcomas-Lessons Learned and Questions Raised Lee J. Helman, M.D. Scientific Director for Clinical Research,Center.
Malignant Melanoma and CDKN2A
TSC and LAM: Current Treatment Options and Clinical Trials
Not division…But growth. Cells must grow PI3K GFR Akt Rheb Ras mTOR Tuberin/ Hamartin PTEN Neurofibromin Tuberous sclerosis complex Neurofibromatosis.
Hypertrophic signalling Identify contraction-induced growth signals Describe the composition and regulation of mTORC1 Describe the effectors of mTOR Explain.
1. p53 Structure, Function and Therapeutic Applications Provider: Dr.Davood Nourabadi(PhD,medical physiology) mdphysiology.persianblog.ir.
TSC2 and Tuberous Sclerosis
Specialized signaling pathways 1: RTK associated pathways
Regulation of Cell Division Coordination of cell division A multicellular organism needs to coordinate cell division across different tissues & organs.
Lecture 10: Cell cycle Dr. Mamoun Ahram Faculty of Medicine
TSC1 and Facial Angiofibromas
TSC1/Hamartin and Facial Angiofibromas Biology 169 Ann Hau.
Insulin and Amino Acid Signaling Through mTOR in Perfused Rat Liver Jessica Biegler.
Merlin, tumor suppressor 박건수 Cancer Genetics.
Interna tional Neurourology Journal 2015;19:55-66 Is 5´-AMP-Activated Protein Kinase Both Jekyll and Hyde in Bladder Cancer? Wun-Jae Kim Department of.
Tuberous Sclerosis Abdullah M. Al-Olayan MBBS, SBP, ABP
TSC1 Tuberous Sclerosis 1
Date of download: 7/5/2016 Copyright © 2016 McGraw-Hill Education. All rights reserved. Insulin signaling pathways. The insulin signaling pathways provide.
Cellular hypertrophy Control of protein accretion –Endogenous Nutrient status Functional adequacy History –Exogenous Nutrient availability Growth factors.
By: Jubair Aziz, Jing Nan Qiao, Bita Janzadeh
MYC, Metabolism and Cancer
by Rogelio Zamilpa, and Merry L. Lindsey
Tuberous Sclerosis TSC2/ Tuberin Alison Chappell.
TSC1 in Facial Angiofibromas
TSC2 GENE ENCODES FOR TUBERIN
PTEN (a.k.a. MMAC1 and TEP1) and Cowden’s Disease
Graduate School of Medical Science & Egineering
Figure 1 mTOR pathway activation
Kinase inhibitors: Vice becomes virtue
Overgrowth Syndromes Caused by Somatic Variants in the Phosphatidylinositol 3- Kinase/AKT/Mammalian Target of Rapamycin Pathway  Gozde Akgumus, Fengqi.
PTEN Tumor Suppressor Extraordinaire
Figure 3 Physiological regulation of autophagy in the heart
Alexander L. Fogel, BS, Sharleen Hill, MD, Joyce M.C. Teng, MD, PhD 
Figure 1 mTOR complex biology
In-vitro regulation of primordial follicle activation: challenges for fertility preservation strategies  Michael J. Bertoldo, Kirsty A. Walters, William.
Review AMP-activated protein kinase: Ancient energy gauge provides clues to modern understanding of metabolism CELL METABOLISM : JANUARY 2005 · VOL.
PTEN Tumor Suppressor and Cancer
The pathway signalling starts with the binding of insulin or growth factors to insulin receptors. The pathway signalling starts with the binding of insulin.
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer  Vassiliki Papadimitrakopoulou,
Maria M. Mihaylova, David M. Sabatini, Ömer H. Yilmaz  Cell Stem Cell 
Identification of TOR Signaling Complexes
Is REDD1 a Metabolic Éminence Grise?
Figure 1 The insulin signalling pathway
Rapamycin: One Drug, Many Effects
FGFR Signaling as a Target for Lung Cancer Therapy
Autophagy in kidney disease and aging: lessons from rodent models
An Emerging Role of mTOR in Lipid Biosynthesis
mTORC1 Signaling: A Double-Edged Sword in Diabetic β Cells
AKT/PKB Signaling: Navigating the Network
Figure 1 The mTOR signalling pathway
AKT/PKB Signaling: Navigating Downstream
Rapamycin: One Drug, Many Effects
Multifunctional Tumor Suppressor
mTOR Regulation by JNK: Rescuing the Starving Intestinal Cancer Cell?
Simon Ekman, MD, PhD, Murry W. Wynes, PhD, Fred R. Hirsch, MD, PhD 
Volume 13, Issue 15, Pages (August 2003)
Volume 69, Issue 11, Pages (June 2006)
Tobias B. Huber, Gerd Walz, E Wolfgang Kuehn  Kidney International 
Figure 2 Domain/structural organization of mTOR protein with the positions of the mutations indicated Domain/structural organization of mTOR protein with.
BC Basics 2017.
Dysregulation of the mTOR Pathway Secondary to Mutations or a Hostile Microenvironment Contributes to Cancer and Poor Wound Healing  Richard A.F. Clark,
Nutrient Sensing, Metabolism, and Cell Growth Control
Presentation transcript:

TOR ( target of rapamycin) signaling Apr 4, 2005

serine/threonine protein kinase PI-3K-kinase related kinase (PIKK)superfamily Central role of TOR in cell growth and proliferation (disruption of gene encoding TOR results in lethality in all species)

TOR: integrator of nutrient and growth factor Coordinator of cell growth and proliferation Nutrients and Growth factor TOR Transcription, translation and ribosome biogenesis Cell growth (in crease in proliferating or non-proliferating cell mass and size via macromolecular biosynthesis) Cell proliferation (increase in cell number) Coupled, allowing cells to proliferate continuously while maintaining their size maintain individual cells, organs and whole organisms a characteristic size(Dysregulation of TOR signaling result in pathological changes in organ size, and diseases such as cancer, heart hypertrophy, muscular atrophy)

caAkt: Constitutively active Akt kdAkt: Kinase deficient Akt

Myostatin 肌抑素

 Discovery of rapamycin and identification of TOR  Structure of TOR protein  TOR signaling Upstream Downstream  TOR-binding proteins  TOR function  TOR and diseases  Future directions

Discovery of rapamycin and identification of TOR  1970s, rapamycin purification from Streptomyces hygroscopicus in Easter Island, antifungal activity  inhibit mammalian cell, especially immune system (B and T) cell proliferation as well as against solid tumors, potential immunosuppressant and anticancer drug  1989, FKBP12 (FK506-binding protein of 12 kDa, isomerase, protein folding) in Saccharomyces cerevisiae, direct receptor of rapamycin  1991, Genetic screens for mutations that rendered for S. cerevisiae resistant to the growth inhibitory effect of rapamycin identified two target of rapamycin proteins: TOR1 and TOR2

 , identification and cloning mTOR (mammalian target of rapamycin) from human rat and mouse. also named FRAP (FKBP-12-rapamycin-associated protein), RAFT (rapamycin and FKBP12 target), RAPT (rapamycin target) and SEP (sirolimus effector protein)  1999, TOR inhibitor rapamycin was approved as an immunosuppressant (inhibit kidney transplant rejection) and cardiology drug (restenosis after angioplasty 血管形成术后再狭窄 ) by FDA  rapamycin analogs CCI-779 and RAD001 are currently being tested in phase III clinical trials  An example of investigative power of “ Chemical genetics ” (use drugs or bioactive compounds as probes for dissection of signaling pathways)

 Structure of TOR protein  Large (290 kDa)  evolutionarily conserved (40-60% identical among mammals, flies, worms and yeast)  member of PIKK superfamily (MEC1, TEL1, RAD3, MEI41, DNA-PK, ATM, ATR and TRRAP)  HEAT repeats (Huntingtin, EF3, A subunit of PP2A and TOR motifs): 20 tandemly helical repeated, protein- protein interaction  FAT (FRAP-ATM-TRRAP) and FATC (FAT C-terminus): modulation of catalytic kinase activity  FRB (FKPP12-rapamycin binding domain)  Kinase domain  Repressor domain: auto-inhibitory domain

 Structure of mTOR protein

 TOR signaling (in mammalian cells)

 TOR upstream signaling  Growth factor/RTK  IRS: insulin receptor substrate  PI-3K/Akt/PKB  PTEN: phosphatase and tensin homologue deleted on chromosome ten (mutated in multiple advanced cancers, MMAC), a lipid phosphatase  PDK1: phosphoinositide-dependent protein kinase1  TSC1: tuberous sclerosis( 结节性脑硬化 ) complex 1(hamartin 错构瘤蛋白 );  TSC2 : tuberin 马玲薯球蛋白

 TOR upstream signaling  Rheb: small GTPase, TSC2 function as Rheb- GAP, shifting to Rheb-GDP;Rheb-GEF shifting to Rheb-GTP?  AMPK:AMP-dependent protein kinase  LKB1: key regulator of AMPK activity, mutated in Peutz-Jeghers Syndrome  Raptor: regulatory associated protein of mTOR  G  L(mammalian)or LST8 (yeast)

 TOR downstream pathway  S6K: p70 S6 kinase  S6 protein: 40S ribosomal protein, drive 5’ TOP (terminal oligopyrimidine tract) mRNA translation  4EBP1: eIF4E binding protein  eIF4E: eukaryotic translation initiation factor 4E recognizes the 5’ end cap of mRNA, increase key growth-promoting proteins, cyclin D1, c-Myc  cdks: cyclin-dependent kinase  pRb: protein retinoblastoma ( 眼癌 )  PP2A: protein phosphatase 2A

 TOR-binding proteins in yeast TORC1: AVO1, AVO2, AVO3, TOR2, LST8 controls actin organization, not a rapamycin target TORC2: TOR1, TOR2, KOG1, LST8

 TOR-binding proteins in mammalian cell raptor: regulatory associated protein of mTOR G  L: mammalian LST8,

 Raptor: regulatory associated protein of mTOR

 TOR function  Brain development learning and memory formation  apoptosis

 TOR inhibit autophagy

 TOR and apoptosis

 TOR and diseases  cancer  heart hypertrophy  muscular atrophy  Hamartoma syndromes  Inherited human dieases

 TOR and Cancers

mTOR and Hamartoma syndromes

Tor and Inherited human dieases

 Future directions  TOR deficiency in C. elegans doubles lifespan, whether TOR controls lifespan in mammals ?  How TOR senses and is activated by the presence of nutrients such as amino acid?  Downstream targets and cellular processes that are regulated by TOR  Role of TOR in apoptosis?  Understanding TOR signaling in neurons and muscle cells lead to new therapy for muscular wasting and memory impairment  TOR-binding proteins, gel filtration 2M